Why I'm kicking myself I missed out on CSL shares

I'm still kicking myself on selling out of CSL Limited (ASX:CSL) shares. Here's why.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It was March 2015, my hair was long, summer was on the run and I was about to buy my first bunch of ASX shares. After doing some reading and research, I had narrowed my selection to 5 or 6 ASX shares that I considered worthy of my first investment dollars.

Among this list was biotech company CSL Limited (ASX: CSL). I was enamoured with the company's products, its already impressive stock price growth and its dominance in the medical space and so went ahead and purchased about 35 shares at around $94 (read it and weep).

a woman

The CSL story

CSL is a true innovator and its blood plasma production remains one of the best and most fortified earning streams amongst medical stocks on the ASX. CSL's work with researching and manufacturing influenza vaccines through its Seqirus division places it at the forefront of the fight against the flu (this year's deadly flu season is a tragic reminder of the importance of this work).

Fast forward about three years and CSL had been my standout stock performer. Most of the other (in hindsight, pretty poor) stock picks had either gone backwards or stayed depressingly static – but CSL had charged ahead. I watched the stock price climb to $120, then to $140. At $150 I had thoughts about 'cashing out' and 'taking the profit', because that what the pros do and I thought I was a bit of a genius for latching onto such a winner. Finally, I relented and sold out at $161, taking an 80% profit and feeling pretty good. The price-to-earnings (P/E) ratio for CSL was very high (sitting around 40 if I remember) and I thought that I had ridden the wave to its height and it was about to crash, and I may as well take the cash off the table.

Alas, I then had to endure watching CSL smash through the $200 mark, then $220 and finally $230. Although CSL has since pulled back, it still has a P/E ratio in the high 30s and I learnt my lesson…

Foolish takeaway

If you get a fantastic company on the cheap, never, ever sell unless you have to! Good companies give back by compounding your money in a continuous cycle and the longer you hold the shares, the richer you will become. I wish I could go back and not hit the sell button – I have spent the last two years waiting for a 'buy-the-dip' opportunity to get back in (that still hasn't materialised). But such is life…

Sebastian Bowen (sadly) has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A group of people in suits watch as a man puts his hand up to take the opportunity.
Growth Shares

A rare buying opportunity to buy 1 of Australia's top shares?

This stock has a lot to offer for investors wanting to beat the market…

Read more »

Red buy button on an Apple keyboard with a finger on it.
Growth Shares

2 little-known ASX shares that could make big returns

Experts are bullish about the potential of these stocks.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.
Growth Shares

2 high-quality ASX stocks to buy and hold long term

Brokers see the dip as a compelling long-term buy with 33% to 44% upside.

Read more »

a man wearing casual clothes fans a selection of Australian banknotes over his chin with an excited, widemouthed expression on his face.
Growth Shares

3 fantastic ASX shares that could help build long-term wealth

Analysts think these shares are in the buy zone right now.

Read more »

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Growth Shares

2 ASX 200 shares I rate as top buys for growth

These sizeable businesses could scale significantly from here…

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Growth Shares

Where to invest $7,000 in ASX shares during April

I’m optimistic that these ASX shares could beat the stock market.

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Growth Shares

3 ASX 200 shares that could quietly compound for years

Let's see what sets these shares apart from the crowd.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Growth Shares

3 ASX shares tipped to grow 100% or more in the next 12 months

Here’s how much these exciting stocks could rise in the year ahead.

Read more »